Monoclonal Antibodies as Potential Treatment Drugs for Nsp15 and 3CLpro Proteins
Physical Chemistry Research
; 11(3):623-629, 2023.
Article
in English
| Scopus | ID: covidwho-2100687
ABSTRACT
Selected monoclonal antibody molecules were conducted using the antibody-antigen docking mode, as well as the antibody-antigen docking approach. The objective of the study was to check the effects of Cetuximab COVID-19 proteins (Nsp15 and 3CLpro) by using antibody-antigen docking mode, as well as the antibody-antigen docking approach. The results of molecular docking revealed that Cetuximab, a cancer-fighting antibody, ranks first among antibodies to both COVID-19 proteins (Nsp15 and 3CLpro). In cetuximab-3CLpro and cetuximab-Nsp15 complexes, the antigen interacts with both antibody chains, H and L. According to the findings, Cetuximab can be added to the COVID-19 treatment protocol, which may have the desired effect of inhibiting viral replication and decreasing mortality by targeting COVID-19 proteins (Nsp15 and 3CLpro). Validation of these computational findings will require additional in vitro and in vivo research, which can be considered as a contribution in the field of biotechnology © 2023, Physical Chemistry Research.All Rights Reserved.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
Physical Chemistry Research
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS